Sugi Predict

Sugi Predict / Compounds / SCHEMBL9957463

SCHEMBL9957463

SCHEMBL9957463

CN(C(=O)Cl)C1CCN(C(=O)O)CC1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL3 Q96JM7 2/20 0.40
▸ NPY5R Q15761 5/20 0.36
▸ PDK2 Q15119 3/20 0.35
▸ DRD2 P14416 1/20 0.34
▸ HTR2A P28223 1/20 0.34
▸ HTR2C P28335 1/20 0.34
▸ HTR2B P41595 1/20 0.34
▸ SIGMAR1 Q99720 1/20 0.34
▸ ALDH1A1 P00352 3/20 0.33
▸ HSD11B1 P28845 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ TSHR P16473 1/20 0.32
▸ KCNH2 Q12809 1/20 0.32
▸ KDM1A O60341 1/20 0.32
▸ MAOA P21397 1/20 0.32
▸ MAOB P27338 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3831586 0.82 DPP4 (0.43) L3MBTL3NPY5RPDK2L3MBTL1
SCHEMBL16439286 0.80 ALDH1A1 (0.48) HTR2AHTR2CALDH1A1L3MBTL1
SCHEMBL3104303 0.79 L3MBTL3 (0.58) L3MBTL3NPY5RL3MBTL1KDM1AMAOA
SCHEMBL28684039 0.79 ALDH1A1 (0.36) SIGMAR1ALDH1A1HSD11B1L3MBTL1
SCHEMBL8053344 0.79 — —
SCHEMBL27766845 0.78 CCR5 (0.40) L3MBTL3NPY5RHSD11B1
SCHEMBL6414922 0.78 L3MBTL3 (0.43) L3MBTL3NPY5RALDH1A1L3MBTL1
SCHEMBL26683504 0.77 L3MBTL3 (0.40) L3MBTL3NPY5RPDK2DRD2HTR2A
SCHEMBL9957386 0.77 — —
SCHEMBL16415863 0.76 EPHX1 (0.51) HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117295747-A Anti-cancer nuclear hormone receptor targeting compounds 诺维逊生物股份有限公司 2023-12-26 — — CN disclosed
US-11834458-B2 Anti-cancer nuclear hormone receptor-targeting compounds NUVATION BIO INC. (US) 2023-12-05 — — US disclosed
US-20200255412-A1 Imidazolecarboxamides and Their Use as FAAH Inhibitors BIAL-PORTELA & CA SA (PT) 2020-08-13 — — US disclosed
EP-2655323-B1 INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES LEO LABORATORIES LTD (IE) 2017-12-20 — — EP disclosed
US-20170217910-A1 INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES LEO LABORATORIES LIMITED (IE) 2017-08-03 — — US disclosed
US-9708286-B2 Ingenol-3-acylates III and ingenol-3-carbamates LEO LABORATORIES LIMITED (IE) 2017-07-18 — — US disclosed
EP-3024825-B1 IMIDAZOLECARBOXAMIDES AND THEIR USE AS FAAH INHIBITORS BIAL - PORTELA & Cª S A (PT) 2017-06-21 — — EP disclosed
US-20160176854-A1 Imidazolecarboxamides and Their Use as FAAH Inhibitors BIAL-PORTELA & CA, S.A. (PT) 2016-06-23 — — US disclosed
EP-3027610-A1 UREA COMPOUNDS AND THEIR USE AS FAAH ENZYME INHIBITORS BIAL - Portela & Cª S.A. (PT) 2016-06-08 — — EP disclosed
EP-3024825-A1 IMIDAZOLECARBOXAMIDES AND THEIR USE AS FAAH INHIBITORS Bial-Portela & CA, S.A. (PT) 2016-06-01 — — EP disclosed
CN-105593226-A Urea compounds and their use as FAAH enzyme inhibitors BIAL-PORTELA & CA S A 2016-05-18 — — CN disclosed
US-20150291551-A1 INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES LEO LABORATORIES LIMITED (IE) 2015-10-15 — — US disclosed
US-9102687-B2 Ingenol-3-acylates III and ingenol-3-carbamates LEO LABORATORIES LIMITED (IE) 2015-08-11 — — US disclosed
WO-2015016729-A1 UREA COMPOUNDS AND THEIR USE AS FAAH ENZYME INHIBITORS BIAL - PORTELA & Cª, S.A. (PT) 2015-02-05 — — WO disclosed
WO-2015016728-A1 UREA COMPOUNDS AND THEIR USE AS FAAH ENZYME INHIBITORS BIAL - PORTELA & Cª, S.A. (PT) 2015-02-05 — — WO disclosed
WO-2015012708-A1 IMIDAZOLECARBOXAMIDES AND THEIR USE AS FAAH INHIBITORS BIAL - PORTELA & Cª, S.A. (PT) 2015-01-29 — — WO disclosed
US-20140303150-A1 INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES LEO LABORATORIES LIMITED (IE) 2014-10-09 — — US disclosed
EP-2655323-A1 INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES LEO LABORATORIES LIMITED (IE) 2013-10-30 — — EP disclosed
WO-2012083953-A1 INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES LEO PHARMA A/S (DK) 2012-06-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200255412-A1 Imidazolecarboxamides and Their Use as FAAH Inhibitors FAAH, FAAH2, AADAC L3MBTL3 4746/4885NPY5R 1006/4885PDK2 3879/4885
US-20170217910-A1 INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES RXRB, RXRA, RXRG L3MBTL3 2778/4885NPY5R 2085/4885PDK2 3799/4885
US-11834458-B2 Anti-cancer nuclear hormone receptor-targeting compounds NCOA1, NCOR1, NCOA3 L3MBTL3 2873/4885NPY5R 3063/4885PDK2 815/4885
US-20160176854-A1 Imidazolecarboxamides and Their Use as FAAH Inhibitors FAAH, FAAH2, AADAC L3MBTL3 4746/4885NPY5R 1006/4885PDK2 3879/4885
US-20150291551-A1 INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES RXRB, RXRA, RXRG L3MBTL3 2778/4885NPY5R 2085/4885PDK2 3799/4885
US-20140303150-A1 INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES RXRB, RXRA, RXRG L3MBTL3 2778/4885NPY5R 2085/4885PDK2 3799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.